A 3-Month, Phase 1, Open-label, Fixed-dose, first-in-human study to access the safety, tolerability and pharmacokinetics of Risperidone Subcutaneous Implants in patients with Schizophrenia

Trial Profile

A 3-Month, Phase 1, Open-label, Fixed-dose, first-in-human study to access the safety, tolerability and pharmacokinetics of Risperidone Subcutaneous Implants in patients with Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Endo Pharmaceuticals
  • Most Recent Events

    • 20 Feb 2018 New trial record
    • 01 Jan 2018 Results assessing Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in two phase 1 studies, published in the Clinical Pharmacology in Drug Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top